This Stock Is a Train Wreck

The problem with a train wreck isn't the first car that goes off the track, but all the ones farther back that come crashing along behind it.

That seems an apt metaphor for Genzyme (Nasdaq: GENZ  ) . Until recently, everything was going fine for the biotech drug developer. Revenue growth averaged 22% annually from 2003 through 2008. Then the first car slid off the track, as the Food and Drug Administration announced a three-month delay on its decision about allowing larger-scale production of Genzyme's Myozyme.

When the FDA finally made its decision in March, the news wasn't what Genzyme was hoping for. The agency said the company needed to clear up a warning letter about problems the FDA discovered at one of Genzyme's manufacturing plants.

Manufacturing issues continued in June, when Genzyme had to shut down operations at a plant because of contamination. That led to drug shortages, causing Genzyme to show its first decline in quarterly year-over-year sales in a decade.

The plant got cleaned and back up and running, but unfortunately, new issues cropped up last week. On Friday the FDA said that about 1% of the vials coming out of the company contain bits of steel, rubber and fiber. The agency didn't recall the drugs because they treat diseases that don't have any additional treatment options. But it doesn't make the company look good in the eyes of the agency that controls its marketing applications.

It shouldn't have come as a big surprise this week that once again, the FDA failed to approve the large-scale version of Myozyme. Considering the long delay, Genzyme is abandoning that scale, which will be called Lumizyme if it's ever approved. It now plans to try and get the FDA to approve an even larger-scale production used in Europe.

The train cars haven't stopped piling up yet, though. Yesterday, Genzyme announced that it was dropping the development of a follow-on to Renvela, which removes phosphates in patients with chronic kidney disease. The follow-on drug didn't work any better than Renvela.

After this string of bad luck and missteps, is Genzyme a bad-news buy or not? Its shares are down 40% since August of 2008. That year, the company brought in $2.99 per share, excluding one-time issues. If it could get earnings back to 2008 levels -- demand for its product hasn't changed, although there's potential competition from new products from Shire (Nasdaq: SHPGY  ) and Protalix BioTherapeutics (NYSE: PLX  ) -- Genzyme would have a P/E of around 16.6.

That's much lower than its previous heights, but after all its missteps, it no longer deserves those lofty past valuations. Genzyme's midsized biotech brethren, Amgen (Nasdaq: AMGN  ) and Biogen Idec (Nasdaq: BIIB  ) , might be better choices -- at least until Genzyme proves it has the trains back on schedule.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 19, 2009, at 6:09 PM, BIGJIMT wrote:

    SPEAKING OF TRAIN WRECKS, I SAID ON THIS SITE AND MANY OTHERS THAT 'MRNA' WILL GO BACK UNDER $1 DOLLAR AFTER 'MRNA' HIT $1.46 ON OCT.12TH.

    OF COURSE THE FOOL'S WOULDN'T LISTEN. WHO AM I? EVEN THOUGH I HAVE MADE THE RIGHT CALLS FOR TWO CONSECUTIVE YEARS IN A ROW. BUT TODAY THE STOCK CLOSED AT $.84 CENTS, DOWN $-.62 CENTS FROM OCT.12TH. ALREADY.

    WHERE IS THE 2010 EXPENSE MONEY?

    TO MANY NEGATIVES FROM NASDAQ WARNING LETTER, NO SERIOUS EARNINGS INCOME, AND TOO EARLY A PRE-CLINICAL STAGE COMPANY.

    GOOD LUCK TO THOSE STILL HANGING ON, YEAR END SELLING WILL START SOON!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1048220, ~/Articles/ArticleHandler.aspx, 10/2/2014 9:02:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement